LogicBio Therapeutics Inc

NASDAQ:LOGC   3:59:13 PM EDT
0.44
+0.02 (+4.91%)
Products, Other Pre-Announcement

LogicBio Therapeutics Announces FDA Lifts Clinical Hold On SUNRISE Trial In Pediatric Patients With Methylmalonic Acidemia

Published: 05/09/2022 13:48 GMT
LogicBio Therapeutics Inc (LOGC) - Logicbio Therapeutics Announces FDA Lifts Clinical Hold on Sunrise Trial in Pediatric Patients With Methylmalonic Acidemia.
Logicbio Therapeutics - in Connection With Lifting of Clinical Hold, Co Amended Sunrise Protocol in a Manner That Reflected Its Dialogue With FDA.
Logicbio Therapeutics Inc - Expects to Proceed With Dosing After It Implements Changes to Sunrise Protocol.
Logicbio-after Lifting of Clinical Hold, Co Reinstating Previous Guidance & Expects to Present Interim Clinical Data From Sunrise Trial by End of Q2.